Coherus BioSciences Inc (CHRS) stock forecast · rev $26.6M
Coherus BioSciences Inc (CHRS) is a biotechnology company listed on US.
This CHRS forecast page states what the cached financials imply — not a price target and not a guarantee. Coherus BioSciences Inc outlooks on Lician start from reported revenue and the latest filing, then you decide.
Latest reported CHRS revenue for 2026-06-30 was $26.6M. Net income was -$59.0M. CHRS currently screens at market cap $223.7M.
Period-over-period revenue change is not in cache for CHRS, so this page does not invent a growth rate.
CHRS currently screens at market cap $223.7M. Stretching today's multiple into 2026 without a filing reason is how thin forecast pages get ignored.
When the next CHRS 10-Q or 8-K lands, this outlook should move. Until then the SEC page is the source.
Not a prediction market. For the live quote and the full model, use the CHRS stock page.
Not investment advice.